Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.Anthony W. Tolcher, Yifan Zhai, Alexander I. Spira et al.|Journal of Clinical Oncology|2021Cited by 23
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).Richard S. Finn, Jordi Bruix, R. T. P. Poon et al.|Journal of Clinical Oncology|2011Cited by 17
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Med|2025Cited by 6
Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).Angel Qin, Yifan Zhai, Gregory P. Kalemkerian et al.|Journal of Clinical Oncology|2021Cited by 5